Wedbush Forecasts Reduced Earnings for Adherex Technologies

Key Points

• Wedbush analysts have reduced their Q3 2025 earnings per share estimate for Adherex Technologies from $0.40 to ($0.06), indicating a significant downward revision.
• Despite the lowered earnings forecast, two analysts recently upgraded their ratings on Adherex Technologies, with Craig Hallum increasing its target price from $13.00 to $14.00 while issuing a "buy" rating.
• Adherex Technologies' stock has shown volatility, trading down 2.0% recently and reaching a 52-week high of $9.92, with a market capitalization of approximately $230.82 million.

Adherex Technologies Inc. (NASDAQ:FENC - Free Report) - Investment analysts at Wedbush decreased their Q3 2025 earnings per share estimates for shares of Adherex Technologies in a research report issued on Monday, October 13th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.06) per share for the quarter, down from their prior estimate of $0.40. The consensus estimate for Adherex Technologies' current full-year earnings is ($0.11) per share. Wedbush also issued estimates for Adherex Technologies' Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.24) EPS, Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at $0.37 EPS, Q3 2026 earnings at $0.04 EPS, Q4 2026 earnings at $0.06 EPS, FY2027 earnings at $0.68 EPS and FY2028 earnings at $1.55 EPS.

A number of other equities research analysts also recently commented on the company. Craig Hallum increased their price target on Adherex Technologies from $13.00 to $14.00 and gave the company a "buy" rating in a research note on Friday, August 15th. Zacks Research cut Adherex Technologies from a "strong-buy" rating to a "hold" rating in a report on Friday, August 15th. HC Wainwright reissued a "buy" rating and issued a $13.00 target price on shares of Adherex Technologies in a report on Thursday, August 21st. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Adherex Technologies in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Adherex Technologies from a "hold" rating to a "buy" rating in a research report on Friday, October 3rd. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $13.33.

Adherex Technologies Stock Down 2.0%

FENC opened at $8.27 on Wednesday. The firm has a 50-day simple moving average of $8.82 and a two-hundred day simple moving average of $7.81. Adherex Technologies has a 52 week low of $3.96 and a 52 week high of $9.92. The company has a market capitalization of $230.82 million, a PE ratio of -19.69 and a beta of 0.64.

Adherex Technologies (NASDAQ:FENC - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.05). The firm had revenue of $9.76 million for the quarter, compared to analysts' expectations of $9.52 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in FENC. Jane Street Group LLC purchased a new stake in Adherex Technologies in the first quarter valued at about $90,000. AQR Capital Management LLC purchased a new position in shares of Adherex Technologies in the 1st quarter valued at approximately $66,000. Nuveen LLC acquired a new stake in Adherex Technologies in the 1st quarter worth approximately $158,000. Finally, AIGH Capital Management LLC purchased a new stake in Adherex Technologies during the 1st quarter worth approximately $2,199,000. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Adherex Technologies

In other Adherex Technologies news, Director Rosty Raykov sold 10,000 shares of Adherex Technologies stock in a transaction dated Monday, October 6th. The stock was sold at an average price of $9.78, for a total value of $97,800.00. Following the transaction, the director owned 82,501 shares in the company, valued at $806,859.78. The trade was a 10.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Southpoint Capital Advisors Lp sold 20,609 shares of Adherex Technologies stock in a transaction that occurred on Thursday, October 9th. The stock was sold at an average price of $9.35, for a total transaction of $192,694.15. Following the completion of the transaction, the insider directly owned 4,010,100 shares in the company, valued at approximately $37,494,435. The trade was a 0.51% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 88,889 shares of company stock valued at $831,426. 10.98% of the stock is owned by insiders.

About Adherex Technologies

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.